mandate, makes the Company challengingly control the cost of sales. Consequently, there is a loss from CPO that its cost is higher than the Company’s average selling price of 3.00 Baht/Kilogram. The amended
, compared with selling expenses of Baht 19.87 million in the same period of the previous year which decreased by Baht 5.04 million or 25.4 percent. This is because there is no obligation in current quarter to
Equity Share Value Size of Transaction = % Number of shares issued as consideration Total number of issued and paid-up shares of the Company = Cannot be calculated as there is no issuance of shares As the
. Registered capital THB 1,000,000 Number of Shares 1,000 shares Par value per share THB 1,000 Paid-up per share THB 1,000 Director of Leyland There is one director of Leyland namely Mr. Pongsan Leelaprad
million and the selling expense to revenue from main business ratio is at the rate of 1%. There is no significant change of selling expense from those of the prior year. Administrative expenses In 3Q17, the
prepaid numbers in the country. There is still two third of customers in prepaid market which the Company sees the opportunity in steady growth in 2018. The Company plans to launch new services, e.g. money
be a potential market in the future. For Medical Devices; There is still intense competition in both domestic and foreign markets. Market leaders use price strategies to gain market share. But the
property, plant and equipment. Income tax expenses In 2017, the Group has the income tax expenses of Baht 61 million and the income tax expenses to revenue from main business ratio is 1%. There is no
maximize market opportunities in 2018.” 2. Outlook General economic conditions are favorable: there is growing expectation that Q4 2017 GDP growth in Thailand will have accelerated to 4.5% y/y (versus 4.3
from the existing and develop the entrance of the area to let large trucks are able to enter into the area. (c) The shortcut is unlikely to be used because there is dirt road and holes in the middle part